Human in vivo Th17 cell responses in cutaneous immunity to Staphylococcus aureus
Human in vivo Th17 cell responses in cutaneous immunity to Staphylococcus aureus
批准号:
9196957
负责人:
Lloyd S Miller
金额:
$24.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-01 至 2018-05-31
关键词:
AIDS/HIV problemAbscessAntibiotic ResistanceAntibiotic TherapyAntibioticsAntibodiesAntigensAreaBiological ModelsBloodCD4 Positive T LymphocytesCandida albicansCellsClinicalClinical TrialsCommunitiesCutaneousDNA Sequence AlterationDevelopmentDiabetes MellitusEpidemicFailureFutureGoalsHematopoieticHereditary DiseaseHospitalizationHospitalsHost DefenseHumanHuman GeneticsIgEImmuneImmune responseImmunityIndividualInfectionInfectious Skin DiseasesInpatientsInterleukin-17MediatingMulti-Drug ResistanceMusMutationMyeloid CellsNeutrophil InfiltrationOutpatientsPatientsPublic HealthRecombinantsRecruitment ActivityResearchRoleSTAT1 geneSiteSkinStaphylococcus aureusStem cellsT cell responseT-LymphocyteTestingTranslatingVaccinationVaccinesVirulentVisitWhite Blood Cell Count procedureabstractingadaptive immunitybasecostcytokinehumanized mousein vivoin vivo Modelinnovationinsightinterestinterleukin-22methicillin resistant Staphylococcus aureusmouse modelneutrophilpre-clinicalpreventreconstitutionresistant strainresponsestemvaccination strategy
中文摘要
项目摘要/摘要
英文摘要
Project Summary / Abstract
The epidemic of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) over the past
two decades has resulted in the emergence of virulent and multi-drug resistant strains that are causing severe
skin infections in healthy people outside of hospitals. These infections are creating a serious public health
concern, especially since antibiotic resistance among CA-MRSA clinical isolates continues to rise. Our ultimate
goal is to gain insights into the specific human immune responses that could be targeted for more effective
vaccination strategies against S. aureus skin infections. This is especially important because all vaccination
attempts against S. aureus to date that were previously effective in preclinical mouse models either had no
efficacy in humans or actually exacerbated the infection. The recruitment of neutrophils to the site of infection
facilitates abscess formation and is required for clearance of S. aureus skin infections. Thus, in this proposal,
we will focus on human Th17 cells and responses since these represent antigen-specific adaptive responses
that might control PMN recruitment. However, a major impediment to investigating the mechanisms of human
neutrophil recruitment is the lack of an in vivo model system with normal human neutrophil numbers. Current
humanized mouse models only possess 1-5% of circulating human neutrophils—far below the 45-70% of
neutrophils found in human blood. To overcome this we will develop humanized mice with more efficient
neutrophil reconstitution to test our overall hypothesis that the human Th17 cell cytokines IL-17A, IL-22 and
IL-26 can promote clearance of a S. aureus skin infection by inducing PMN recruitment. We further
hypothesize that S. aureus-specific CD4+ T cells, and in particular Th17 cells, can promote neutrophil
recruitment and bacterial clearance. In Aim 1, we will determine the mechanisms by which human IL-17A,
IL-22 and IL-26 promote neutrophil recruitment and host defense against a S. aureus skin infection in
humanized mice. In Aim 2, we will determine the role of human Th17 cells in promoting PMN recruitment and
clearing a S. aureus skin infection in humanized mice. Of note, our humanized mouse models will possess
both “matched” human skin and human immune cells, which is highly innovative because this has not been
done before to study S. aureus skin infections. Taken together, our proposal will provide new in vivo
mechanistic insights by which human Th17 cells and cytokines promote neutrophil recruitment and host
defense against S. aureus skin infections. Given that our results will be obtained using optimized humanized in
vivo models, our findings are more likely to translate to humans and provide key information about the specific
human immune mechanisms to target in the future development of an effective S. aureus vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STAT3-mediated immunity to Staphylococcus aureus in skin
-
批准号:9055474
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2016
-
负责人:Lloyd S Miller
-
依托单位:
STAT3 and IL-17-Th17 in skin immunity to MRSA
-
批准号:8903440
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2014
-
负责人:Lloyd S Miller
-
依托单位:
Innate Immune Response to Staphylococcus aureus in Skin
-
批准号:8012861
-
项目类别:
-
资助金额:$33.96万
-
财政年份:2009
-
负责人:Lloyd S Miller
-
依托单位:
Innate Immune Response to Staphylococcus aureus in Skin
-
批准号:7590055
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2009
-
负责人:Lloyd S Miller
-
依托单位:
Innate Immune Response to Staphylococcus aureus in Skin
-
批准号:8417741
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2009
-
负责人:Lloyd S Miller
-
依托单位:
Innate Immune Response to Staphylococcus aureus in Skin
-
批准号:8213386
-
项目类别:
-
资助金额:$33.96万
-
财政年份:2009
-
负责人:Lloyd S Miller
-
依托单位:
Innate Immune Response to Staphylococcus aureus in Skin
-
批准号:7761267
-
项目类别:
-
资助金额:$30.49万
-
财政年份:2009
-
负责人:Lloyd S Miller
-
依托单位:
Host defense against Staphylococcus aureus skin infections
-
批准号:7513375
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2008
-
负责人:Lloyd S Miller
-
依托单位:
Host defense against Staphylococcus aureus skin infections
-
批准号:7651292
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2008
-
负责人:Lloyd S Miller
-
依托单位:
Host defense against Staphylococcus aureus skin infections
-
批准号:7799065
-
项目类别:
-
资助金额:$7.62万
-
财政年份:2008
-
负责人:Lloyd S Miller
-
依托单位:
Cutaneous Host Defense Against Bacterial Infections
-
批准号:7351776
-
项目类别:
-
资助金额:$11.21万
-
财政年份:2005
-
负责人:Lloyd S Miller
-
依托单位:
Cutaneous Host Defense Against Bacterial Infections
-
批准号:7015079
-
项目类别:
-
资助金额:$10.57万
-
财政年份:2005
-
负责人:Lloyd S Miller
-
依托单位:
Cutaneous Host Defense Against Bacterial Infections
-
批准号:6855998
-
项目类别:
-
资助金额:$10.26万
-
财政年份:2005
-
负责人:Lloyd S Miller
-
依托单位:
Cutaneous Host Defense Against Bacterial Infections
-
批准号:7183493
-
项目类别:
-
资助金额:$10.88万
-
财政年份:2005
-
负责人:Lloyd S Miller
-
依托单位:
海外基金